logo
Share SHARE
FONT-SIZE Plus   Neg

Intrexon Files For IPO Of Up To $125 Mln

Biotechnology company Intrexon Corp. has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission to raise up to $125 million in an initial public offering of common stock. The company did not specify the number of shares to be sold and the price range for the proposed offering.

The Germantown, Maryland based company plans to list on the New York Stock Exchange under the ticker symbol XON.

The company said in a preliminary prospectus that it plans to use the proceeds to fund continued investment in research and development platforms and its business development efforts.

Intrexon is a leader in the field of synthetic biology, an emerging and rapidly evolving discipline that applies engineering principles to biological systems

Intrexon, which was founded in 1998, is now controlled by Randal Kirk, who has been the chief executive of the company since 2005.

J.P. Morgan and Barclays are the joint bookrunners on the deal.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
British lender Lloyds Banking Group Plc. Friday reported higher profit in its first half, benefited by increased net interest income and margin as well as lower impairment. Looking ahead, the company lifted its net interest margin forecast. Amgen reported an increase in second-quarter profit, driven by sales of arthritis drug Enbrel and osteoporosis treatments Xgeva and Prolia, and improved margins. Both earnings and sales topped Wall Street estimates. Electronic Arts Inc. (EA) on Thursday reported an increase in profit for the first quarter, reflecting continued strong digital revenues, with both earnings and revenues topping Wall Street estimates. However, shares of the company fell over 4 percent, after having detailed a weak outlook. Redwood...
comments powered by Disqus
Follow RTT